Symphogen
Total Raised
$359.16MInvestors Count
12Funding, Valuation & Revenue
9 Fundings
Symphogen has raised $359.16M over 9 rounds.
Symphogen's latest funding round was a Acquired for on April 3, 2020.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
4/3/2020 | Acquired | 11 | ||||
10/22/2015 | Convertible Note | |||||
5/2/2013 | Series F - II | |||||
1/17/2011 | Series F | |||||
2/6/2009 | Series E |
Date | 4/3/2020 | 10/22/2015 | 5/2/2013 | 1/17/2011 | 2/6/2009 |
|---|---|---|---|---|---|
Round | Acquired | Convertible Note | Series F - II | Series F | Series E |
Amount | |||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 11 |
Symphogen Investors
12 Investors
Symphogen has 12 investors. Servier invested in Symphogen's Acquired funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
4/3/2020 | 4/3/2020 | 1 Acquired | Corporation | France | ||
11/10/2004 | 10/22/2015 | 5 Series C, Series D (2006), Series F (2011), Series F - II (2013), Convertible Note (2015) | Holding Company | Denmark | ||
1/17/2011 | 10/22/2015 | 3 Series F, Series F - II (2013), Convertible Note (2015) | Pension Fund | Denmark | ||
Corporation | Denmark | |||||
Growth Equity | New York |
First funding | 4/3/2020 | 11/10/2004 | 1/17/2011 | ||
|---|---|---|---|---|---|
Last Funding | 4/3/2020 | 10/22/2015 | 10/22/2015 | ||
Investor | |||||
Rounds | 1 Acquired | 5 Series C, Series D (2006), Series F (2011), Series F - II (2013), Convertible Note (2015) | 3 Series F, Series F - II (2013), Convertible Note (2015) | ||
Board Seats | |||||
Type | Corporation | Holding Company | Pension Fund | Corporation | Growth Equity |
Location | France | Denmark | Denmark | Denmark | New York |
Symphogen Acquisitions
1 Acquisition
Symphogen acquired 1 company. Their latest acquisition was Receptor Biologix on January 07, 2009.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
1/7/2009 | Series D | $39.6M | Acquired |
Date | 1/7/2009 |
|---|---|
Investment Stage | Series D |
Companies | |
Valuation | |
Total Funding | $39.6M |
Note | Acquired |
Sources |
Compare Symphogen to Competitors
ImmunoReagents produces polyclonal antibodies and reagents for the pharmaceutical, biotechnology, life science research, and in vitro diagnostics industries. The company offers immunoassay reagents and antibodies used in assays such as ELISA, immunohistochemistry, western blotting, flow cytometry, and immunofluorescence. ImmunoReagents provides antibody purification tools, bulk antibodies, and custom services. It was founded in 2005 and is based in Raleigh, North Carolina.
Humanetics is a clinical stage pharmaceutical company that works on solid tumor cancers and developing countermeasures for radiation exposure. The company creates radiation modulators intended to improve radiation treatments for cancer patients and protect normal tissues from radiation damage. Humanetics' primary product, BIO 300, is under development for use in oncology to sensitizing tumor cells to radiation, and for inflammatory lung diseases as a countermeasure for radiation exposure. It was founded in 1988 and is based in Minneapolis, Minnesota.
Embera NeuroTherapeutics is a clinical stage pharmaceutical company developing treatments for addiction. The company's main product, EMB-001, targets pathways in the stress response system related to addiction. Embera NeuroTherapeutics focuses on cocaine use disorder and nicotine addiction. It was founded in 2005 and is based in Sudbury, Massachusetts.
NovaDigm Therapeutics is a wellness coaching company that provides information on blood sugar balance, metabolic health, inflammation management, and wellness without an emphasis on weight loss. The company includes strength training and increased protein intake as part of its approach to health in midlife. It is based in Grand Forks, North Dakota.
Bellicum Pharmaceuticals is a biopharmaceutical company in the clinical stage involved in the development of cellular immunotherapies. The company is working on treatments for cancer, including hematological and solid tumors, as well as inherited blood disorders, using next-generation product candidates. The focus areas of the company include cellular immunotherapy techniques such as stem cell transplantation and CAR T cell therapy. It was founded in 2004 and is based in Houston, Texas.
ModiQuest is a biotechnology company focused on developing novel therapeutics for inflammatory diseases, particularly in the domain of rheumatoid arthritis. The company specializes in using recombinant antibody technology to create therapeutic leads aimed at treating rheumatoid arthritis and other inflammatory conditions. ModiQuest primarily serves the biopharmaceutical industry with its therapeutic leads designed for co-development or outlicensing. It was founded in 2004 and is based in Netherlands.
Loading...